Wayland Group Confirms “BfARM” award for German Cannabis production

Wayland Group Corp. (CSE:WAYL; FWB:75M; OTCQB:MRRCF)(“Wayland” or the “Company”) today announced that its joint venture DEMECAN GmbH (“DEMECAN”), of which it holds 50% with an option to increase to 60% has been awarded three lots of domestic cannabis production in Germany by the Federal Institute for Drugs and Medical Devices (“BfArM”), after the withdrawal of a competitor’s complaint following an oral court hearing.   

Wayland Group Corp. (CSE:WAYL; FWB:75M; OTCQB:MRRCF)(“Wayland” or the “Company”) today announced that its joint venture DEMECAN GmbH (“DEMECAN”), of which it holds 50% with an option to increase to 60% has been awarded three lots of domestic cannabis production in Germany by the Federal Institute for Drugs and Medical Devices (“BfArM”), after the withdrawal of a competitor’s complaint following an oral court hearing.

DEMECAN is awarded three lots of thirteen total, which makes DEMECAN one of three companies globally to achieve a cannabis license for domestic production in Germany, out of 79 applicants.

DEMECAN will now begin production within Wayland’s Ebersbach facility, following completion of upgrades to quality and security systems.

Additionally, Wayland GmbH has received its narcotics license from the Bundesopiumstelle, the narcotics division of BfArM.

“We have worked hard to build our business to standards which exceed industry norms and are delighted to have been rewarded through this externally validated merit-based award to our joint venture partner DEMECAN in three lots of domestic cannabis production in Germany. In the most highly competitive process for a federal license in the world, to date, we have demonstrated that our team and our joint venture partners can be successful in the most competitive significant new markets. Additionally, receipt of our own narcotics license in Germany demonstrates further the high standards we live by as a company. We are proud to be 1 of 3 in Germany for domestic production, one of four globally for end to end EU-GMP certificated export from Canada and import to the EU, and 1 of 6 globally for EU-GMP certified cannabis production.” Stated Ben Ward – CEO.

About Wayland Group

Wayland is a vertically integrated cultivator and processor of cannabis. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a cannabis cultivation, extraction, formulation, and distribution business under federal licenses from the Government of Canada. The Company also has licenses in Colombia and production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland and, Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, and Argentina, in its effort to enhance lives through cannabis.

Forward Looking Information

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Wayland, please visit our website at www.waylandgroup.com

Contact Information:
Investor Relations
IR@waylandgroup.com

Media Inquiries: media@waylandgroup.com

Corporate Headquarters (Canada)
Wayland Group Corp. (Toronto)
2381 Bristol Circle, Suite 102
Oakville, Ontario, L6H 5S9
Canada
289-288-6274

European Headquarters (Germany)
MaricannGmbH
c/o Wayland
Max Joseph Str. 7
80333 Munich

Source: www.globenewswire.com

Featured
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. for violations of the securities lawsThe investigation focuses on whether the Company issued false andor misleading statements andor failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

read more Show less
Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration Trulieve Cannabis Corp. a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving ...

Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving patients at this location at 9:00 am on Thursday, December 2 and will continue the celebration with all-day festivities and deals. The new location is Trulieve's 110 th dispensary in Florida and its 157 th nationwide.

read more Show less
Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as ...

Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs

B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as the New York Cannabis Control Board recently approved whole flower as part of its medical marijuana offerings in late October.

read more Show less

MARKETS

Markets
TSX20464.60-195.39
TSXV917.92-21.52
DOW34022.04-461.68
S&P 5004513.040.00
NASD15254.05-283.64
ASX7235.90-20.10

COMMODITIES

Commodities
Gold1776.45-5.38
Silver22.38+0.02
Copper4.25+0.01
Palladium1717.50-33.50
Platinum942.00+6.00
Oil65.32-0.25
Heating Oil2.080.00
Natural Gas4.15-0.10